Literature DB >> 9005987

Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis.

J L Brasier1, E P Henske.   

Abstract

It is not known whether mutations in the PKD1 gene cause autosomal dominant polycystic kidney disease (PKD) by an activating (gain-of-function) or an inactivating (loss-of-function) model. We analyzed DNA from cyst epithelial cells for loss of heterozygosity (LOH) in the PKD1 region of chromosome 16p13 using microsatellite markers. 29 cysts from four patients were studied. Five cysts from three patients had chromosome 16p13 LOH. Four of the cysts had loss of two chromosome 16p13 markers that flank the PKD1 gene. In two patients, microsatellite analysis of family members was consistent with loss of the wild-type copy of PKD1 in the cysts. In the third patient, 16p13 LOH was detected in three separate cysts, all of which showed loss of the same alleles. Chromosome 3p21 LOH was detected in one cyst. No LOH was detected in four other genomic regions. These results demonstrate that some renal cyst epithelial cells exhibit clonal chromosomal abnormalities with loss of the wild-type copy of PKD1. This supports a loss-of-function model for autosomal dominant PKD, with a germline mutation inactivating one copy of PKD1 and somatic mutation or deletion inactivating the remaining wild-type copy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005987      PMCID: PMC507786          DOI: 10.1172/JCI119147

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Multilocus polycystic disease.

Authors:  S T Reeders
Journal:  Nat Genet       Date:  1992-07       Impact factor: 38.330

2.  Renal involvement in tuberous sclerosis.

Authors:  J Bernstein; T O Robbins
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

3.  Genetic heterogeneity of polycystic kidney disease in Europe.

Authors:  D J Peters; L A Sandkuijl
Journal:  Contrib Nephrol       Date:  1992       Impact factor: 1.580

Review 4.  Polycystic kidney disease: neoplasia in disguise.

Authors:  J J Grantham
Journal:  Am J Kidney Dis       Date:  1990-02       Impact factor: 8.860

Review 5.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

Review 6.  Autosomal dominant polycystic kidney disease.

Authors:  P A Gabow
Journal:  N Engl J Med       Date:  1993-07-29       Impact factor: 91.245

7.  Linkage disequilibrium in the region of the autosomal dominant polycystic kidney disease gene (PKD1).

Authors:  A Snarey; S Thomas; M C Schneider; S E Pound; N Barton; A F Wright; S Somlo; G G Germino; P C Harris; S T Reeders
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

8.  Cyst-derived cells do not exhibit accelerated growth or features of transformed cells in vitro.

Authors:  F A Carone; S Nakamura; B S Schumacher; P Punyarit; K D Bauer
Journal:  Kidney Int       Date:  1989-06       Impact factor: 10.612

9.  Aberrant epithelial cell growth in autosomal dominant polycystic kidney disease.

Authors:  P D Wilson
Journal:  Am J Kidney Dis       Date:  1991-06       Impact factor: 8.860

Review 10.  Tumor suppressor genes.

Authors:  R A Weinberg
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

View more
  74 in total

1.  Mutation detection of PKD1 identifies a novel mutation common to three families with aneurysms and/or very-early-onset disease.

Authors:  T Watnick; B Phakdeekitcharoen; A Johnson; M Gandolph; M Wang; G Briefel; K W Klinger; W Kimberling; P Gabow; G G Germino
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.

Authors:  M Rafiq Islam; Tamara Jimenez; Christopher Pelham; Marianna Rodova; Sanjeev Puri; Brenda S Magenheimer; Robin L Maser; Christian Widmann; James P Calvet
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 3.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 4.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

Review 5.  A mechanistic approach to inherited polycystic kidney disease.

Authors:  John J Bissler; Bradley P Dixon
Journal:  Pediatr Nephrol       Date:  2005-02-18       Impact factor: 3.714

Review 6.  MicroRNAs in the pathogenesis of cystic kidney disease.

Authors:  Yu Leng Phua; Jacqueline Ho
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

Review 7.  Autosomal dominant polycystic kidney disease and transplantation.

Authors:  Mariusz Niemczyk; Stanisław Niemczyk; Leszek Paczek
Journal:  Ann Transplant       Date:  2009 Oct-Dec       Impact factor: 1.530

8.  Loss of polycystin-1 causes centrosome amplification and genomic instability.

Authors:  Lorenzo Battini; Salvador Macip; Elena Fedorova; Steven Dikman; Stefan Somlo; Cristina Montagna; G Luca Gusella
Journal:  Hum Mol Genet       Date:  2008-06-19       Impact factor: 6.150

9.  Pkd1 transgenic mice: adult model of polycystic kidney disease with extrarenal and renal phenotypes.

Authors:  Almira Kurbegovic; Olivier Côté; Martin Couillard; Christopher J Ward; Peter C Harris; Marie Trudel
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

10.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.